A Single-arm, Open Phase II Clinical Trial of Anti-PD-1 Antibody SHR-1210 Combined With Nimotuzumab as Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital of Zhengzhou University1 site in 1 country45 target enrollmentSeptember 2021

ConditionsEsophageal Squamous Cell Carcinoma

InterventionsNimotuzumab + SHR-1210

DrugsNimotuzumab + SHR-1210

Overview

Phase: Phase 2
Intervention: Nimotuzumab + SHR-1210
Conditions: Esophageal Squamous Cell Carcinoma
Sponsor: The First Affiliated Hospital of Zhengzhou University
Enrollment: 45
Locations: 1
Primary Endpoint: Objective Response Rate (ORR)
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to observe and evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210 combined with nimotuzumab as second-line therapy in patients with advanced cancerous esophageal squamous cell carcinoma.

Detailed Description

The incidence of esophageal cancer is ranked seventh in the world, and the mortality rate ranks sixth in the world. At present, the first-line treatment of advanced esophageal cancer is mainly based on the combination of paclitaxel, cisplatin and fluorouracil. After the failure of first-line treatment, there is no standard second-line treatment. The investigators designed a single-arm, open phase II clinical trial of anti-PD-1 antibody SHR-1210 combined with nimotuzumab as second-line therapy in patients with advanced cancerous esophageal squamous cell carcinoma.

Registry

clinicaltrials.gov

Start Date

September 2021

End Date

September 2023

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

The First Affiliated Hospital of Zhengzhou University

Responsible Party

Principal Investigator

Feng Wang

Director

The First Affiliated Hospital of Zhengzhou University

Eligibility Criteria

Inclusion Criteria

•18\~75 years, both men and women.
•Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)， and locally advanced unresectable, local recurrence or distant metastasis.
•Patients undergoing first-line systemic chemotherapy (which may include platinum, lavender or fluorouracil) progression or intolerance (progress in maintenance therapy after first-line chemotherapy can also be included). Synchronous chemoradiotherapy for postoperative recurrence or metastasis is considered as first-line treatment; For radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or chemoradiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, Count it as a first-line treatment failure.
•At least one measurable/evaluable lesion by RECIST v1.
•And the measurable lesions should not have received local treatment such as radiotherapy (The lesion located in the previous radiotherapy area, if confirmed to progress, and meets the RECIST 1.1 standard, can also be used as a target lesion).
•EGFR immunohistochemistry or FISH detection was positive in tumor tissue samples.
•Tissue samples shall be provided for biomarker analysis, preferably newly acquired tissues, and patients who are unable to provide newly acquired tissues may provide 5-8 pieces of 5um thick paraffin sections that are archived and preserved.
•Eastern Cooperative Oncology Group(ECOG) performance status 0 or
•Life expectancy of ≥ 12 weeks.
•The main organs function normally, that is, the following criteria are met:

Exclusion Criteria

•The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid Hyperfunction; patients with vitiligo; complete remission of asthma in childhood, can be included without any intervention after adult; asthma patients who require bronchodilators for medical intervention cannot be included).
•The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose \>10 mg/day of prednisone or other therapeutic hormones) and continues to be used within 2 weeks prior to enrollment.
•Patients who received EGFR monoclonal antibody or EGFR tyrosine kinase inhibitor;
•Patients who received other PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1;
•Patients with brain metastases with symptoms or symptom control for less than 3 months;
•Patients with any severe and/or uncontrolled diseases, including patients with unsatisfactory blood pressure control (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); patients with grade I or higher myocardial ischemia or myocardial infarction, arrhythmia (including QT interval ≥ 480ms) and grade I cardiac insufficiency; active or uncontrolled severe infection; liver disease such as decompensated liver disease, active hepatitis B (HBV-DNA ≥ 104 copy number / ml or 2000 IU / ml) Or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of detection of the analytical method);
•Imaging studies have shown that the tumor has invaded the important vascular circumference or that the patient is likely to invade the important;
•Pregnant or lactating women.
•Patients with other malignant tumors within 5 years（Except for skin basal cell carcinoma and cervical carcinoma in situ that have been cured).
•Patients with a history of psychotropic substance abuse who are unable to quit or have a mental disorder.